(Q38745588)

6 September 2017

title

Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP. (English)

1 reference

6 September 2017

author

Elizabeth D. Williams

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Stephen Fox

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Dinesh Raghu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Ai-Leen Chan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Twishi Gulati

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Marco J Herold

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Cristina Gamell

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

P J Paul

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

L Lambeth

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

E Takano

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

J Hagekyriakou

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

R L Vessella

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

C Fedele

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

M Shackleton

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

S Williams

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

S Haupt

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Y Haupt

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

19 September 2016

1 reference

6 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

6235-6245

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27641331%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2016.159

31 May 2020

exact match

0 references

cites work

Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Bortezomib as a potential treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

PML tumour suppression and beyond: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

New insights into the role of PML in tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Restoring PML tumor suppression to combat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

The role of PML in tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Identification of a tumour suppressor network opposing nuclear Akt function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Loss of the tumor suppressor PML in human cancers of multiple histologic origins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

E6AP promotes the degradation of the PML tumor suppressor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

HPV E6, E6AP and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

E3 ubiquitin protein ligase, E6-associated protein (E6-AP) regulates PI3K-Akt signaling and prostate cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Multifunction steroid receptor coactivator, E6-associated protein, is involved in development of the prostate gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

LuCaP 35: A new model of prostate cancer progression to androgen independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Efficient tumour formation by single human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Prostate cancer in a transgenic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Neuroendocrine differentiation of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Myc-driven murine prostate cancer shares molecular features with human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

PML, SUMOylation, and Senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

PML-IV functions as a negative regulator of telomerase by interacting with TERT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

PML induces a novel caspase-independent death process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Natural product-like macrocyclic N-methyl-peptide inhibitors against a ubiquitin ligase uncovered from a ribosome-expressed de novo library.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

The role of PML ubiquitination in human malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

E6AP is required for replicative and oncogene-induced senescence in mouse embryo fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FONC.2016.159

21 January 2018

https://pubmed.ncbi.nlm.nih.gov/27641331

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The TRAMP mouse as a model for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159

Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.159